Guggenheim Has Lowered Expectations for Jade Biosciences (NASDAQ:JBIO) Stock Price

Jade Biosciences (NASDAQ:JBIO – Get Free Report) had its target price lowered by equities research analysts at Guggenheim from $47.00 to $41.00 in a research report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim‘s price target suggests a potential upside of 154.03% from the company’s previous close.

JBIO has been the subject of several other research reports. Wedbush reissued an “outperform” rating and set a $47.00 price objective on shares of Jade Biosciences in a research note on Thursday, October 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Jade Biosciences in a report on Friday, September 11th. BTIG Research reaffirmed a “buy” rating and issued a $77.00 price target on shares of Jade Biosciences in a report on Tuesday, October 27th. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Jade Biosciences in a research report on Thursday, October 1st. Finally, Jefferies Financial Group reissued a “buy” rating and set a $48.00 price objective on shares of Jade Biosciences in a report on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Jade Biosciences presently has an average rating of “Moderate Buy” and an average price target of $51.00.

Get Our Latest Stock Report on Jade Biosciences

Jade Biosciences Price Performance

Shares of NASDAQ JBIO opened at $16.14 on Monday. The company has a market cap of $1.03 billion, a P/E ratio of -8.68 and a beta of 1.81. Jade Biosciences has a 52 week low of $9.60 and a 52 week high of $28.00. The business has a 50-day simple moving average of $15.32 and a two-hundred day simple moving average of $18.14.

Jade Biosciences (NASDAQ:JBIO – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.31. Equities research analysts anticipate that Jade Biosciences will post -2.89 EPS for the current year.

Institutional Investors Weigh In On Jade Biosciences

Hedge funds have recently added to or reduced their stakes in the company. Entropy Technologies LP purchased a new position in shares of Jade Biosciences during the 3rd quarter valued at about $145,000. Profund Advisors LLC boosted its stake in Jade Biosciences by 21.5% in the third quarter. Profund Advisors LLC now owns 26,008 shares of the company’s stock worth $365,000 after buying an additional 4,596 shares in the last quarter. Quantinno Capital Management LP boosted its stake in Jade Biosciences by 3.6% in the first quarter. Quantinno Capital Management LP now owns 30,551 shares of the company’s stock worth $429,000 after buying an additional 1,059 shares in the last quarter. Engineers Gate Manager LP bought a new position in Jade Biosciences during the second quarter valued at approximately $503,000. Finally, Bank of America Corp DE grew its position in Jade Biosciences by 2.9% during the first quarter. Bank of America Corp DE now owns 38,598 shares of the company’s stock valued at $542,000 after acquiring an additional 1,086 shares during the last quarter.

Jade Biosciences Company Profile

(Get Free Report)

Jade Biosciences is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease. The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys. Jade’s pipeline is focused on potential therapies for autoimmune conditions.

Further Reading

Analyst Recommendations for Jade Biosciences (NASDAQ:JBIO)

Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.